Prima enrols first patient for cancer trial
06 February, 2012 by Dylan Bushell-EmblingSydney's Prima BioMed (ASX:PRR) has enrolled the first participant for an 800-member trial of its CVac ovarian cancer treatment in post-chemotherapy patients.
Biotechs recover from slump in Q2
03 February, 2012 by Dylan Bushell-EmblingAustralia's life science industry performed relatively well in the December 2011 quarter despite macroeconomic pressures, according to the PricewaterhouseCoopers BioForum Report, with indicators good for the near future.
AusBiotech submits on R&D Tax Incentive Discussion Paper
02 February, 2012 by AusBiotechAusBiotech has lodged a submission in response to the ‘Discussion Paper: R&D Tax Incentive Implementation – realising effective Compliance through Guidance and Education’, which was been conducted by AusIndustry to inform development of its guidance agenda.
Starpharma stocks rise on positive cancer trial results
02 February, 2012 by Dylan Bushell-EmblingStarpharma Holdings (ASX:SPL) shares climbed 12.4% on Wednesday, after the release of positive results from a preclincial study of its dendrimer-docetaxel chemotherapy formulation.
Bionomics deal could push cashflow into black
02 February, 2012 by Dylan Bushell-EmblingThe initial $3m Bionomics has received from its drug development deal with Ironwood Pharmaceuticals could help speed an improvement in cashflow.
Immuron, Monash partner to develop colostrum therapy
31 January, 2012 by Dylan Bushell-EmblingMelbourne-based Immuron (ASX:IMC) and Monash University will collaborate on products aimed at treating C. difficile infections, using Immuron's colostrum technology.
Ascent sold to Watson for $375m
31 January, 2012 by Tim DeanIndian pharmaceutical company Strides Arcolab has sold its Australian generic pharmaceutical manufacturer Ascent Pharmahealth to Watson Pharmaceutical.
Mesoblast shares up following FDA tick for phase II trials
31 January, 2012 by Tim DeanThe US Food and Drug Administration has given the go-ahead for Mesoblast (ASX:MSB) to conduct phase II trials of its stem cell treatment for Type 2 diabetes.
Last chance to take part in AusBiotech’s annual CEO survey
31 January, 2012 by AusBiotechWith the annual CEO Industry Position Survey 2012 closing this week, AusBiotech urges industry leaders to take this opportunity to contribute to the research, enabling an updated and comprehensive view of the Australian biotechnology sector.
Australian-French partnership team up for drug development
30 January, 2012 by Dylan Bushell-EmblingThe Monash Institute of Pharmaceutical Sciences and France's Servier have entered a three-year partnership for drug development research into G Protein-Coupled Receptors.
A promise to a dying friend turns to a quest for a cure
27 January, 2012 by AusBiotechIt began with a promise to a dying friend and became a dedicated quest for a cure for cancer ... and a fundraiser to help.
Xenome raises soothing $8m for pain treatment trial
27 January, 2012 by Dylan Bushell-EmblingBrisbane-based biopharma Xenome Limited has secured $8m in funding from its major investors to pay for a clinical trial of a synthetic peptide as a pain inhibitor.
Biosceptre seeks $15m for anti-cancer monoclonal antibody trials
24 January, 2012 by Tim DeanFunds sought to take monoclonal antibody treatment for multiple cancers into phase I trials on the lead up to IND submission with the US Food and Drug Administration.
BioProspect tightens its focus
24 January, 2012 by Dylan Bushell-EmblingAfter suffering two costly delays, BioProspect (ASX:BPO) is refocusing on gaining local regulatory approval for its lead animal health product.
Australian biotechs attract strong interest at US investor meeting
23 January, 2012 by AusBiotechThe latest AusBiotech investor showcase event in the US has attracted its strongest attendance yet, with the presentations from the participating Australian companies and networking well received.
